You are here
Monday, August 7, 2006
Imaging Study May Help Point Toward More Effective Smoking Cessation Treatments
Results of a new imaging study, supported in part by the National Institute on Drug Abuse (NIDA), National Institutes of Health, show that the nicotine received in just a few puffs of a cigarette can exert a force powerful enough to drive an individual to continue smoking. Researchers found that the amount of nicotine contained in just one puff of a cigarette can occupy about 30 percent of the brain’s most common type of nicotine receptors, while three puffs of a cigarette can occupy about 70 percent of these receptors. When nearly all of the receptors are occupied (as a result of smoking at least 2 and one-half cigarettes), the smoker becomes satiated, or satisfied, for a time. Soon, however, this level of satiation wears off, driving the smoker to continue smoking throughout the day to satisfy cigarette cravings.
“Imaging studies such as this can add immensely to our understanding of addiction and drug abuse," says Elias A. Zerhouni, M.D., Director of the National Institutes of Health. "These findings suggest that drug therapies or vaccines for smoking cessation need to be extremely potent to compete with nicotine, which binds so readily to these receptors.”
The study is published in the August 2006 issue of the Archives of General Psychiatry.
“This study illustrates the powerfully addictive impact of even small amounts of nicotine. Every time a smoker draws a puff from a cigarette, they inhale numerous toxic chemicals that promote the formation of lung cancer, and contribute in a significant way to death and disability worldwide,” says NIDA Director Dr. Nora D. Volkow. “Although many smokers endorse a desire to quit, very few are able to do so on their own, and fewer than half are able to quit long-term even with comprehensive treatment. This study helps explain why.”
The scientists, led by Dr. Arthur Brody of the David Geffen School of Medicine at UCLA, used positron emission tomography (PET) to scan the brains of 11 smokers and assess nicotine distribution there. During the scanning sessions, the participants smoked one of five amounts — none, one puff, three puffs, one full cigarette, or until their craving was satisfied (2 and one-half to three cigarettes). Craving was measured with the Urge to Smoke scale, which assesses responses to 10 craving-related questions. The scientists also conducted magnetic resonance imaging (MRI) to help localize regions on the PET scans.
“We saw on our PET scans that the radiotracer ‘disappeared’ over time as the nicotine receptors became occupied by nicotine from cigarettes,” says Dr. Brody.
The scientists found that the highest levels of nicotine binding occurred in the thalamus (a portion of the brain that acts as a conduit for all sensory information that reaches the brain’s cerebral cortex, and which contains the highest concentration of these nicotine receptors), the brainstem (which controls various automatic functions, such as respiration, heart rate, and arousal), and the cerebellum (the portion of the brain responsible for the coordination of movement and balance). Results of another recently published NIDA-supported study suggest that a portion of the cerebellum called the vermis may be a key factor in modulating the brain’s dopamine and reward systems, and may be more involved in drug abuse and addiction than previously thought.
“Although craving was only reduced with near total occupancy of these receptors, there remains the question of whether other, less common types of nicotine receptors are equally important in tobacco dependence,” says Dr. Brody. “This is an important area of focus for future research.”
“The central findings of the study suggest that typical daily smokers need to have these nicotine receptors almost completely saturated throughout the day, which drives the almost uncontrollable urge to keep smoking,” says Dr. Volkow. “A more complete understanding of how nicotine affects the brain can help us develop better therapies for people looking to quit. In addition, since even low levels of nicotine exposure result in substantial occupancy of these receptors, additional research needs to address the impact of secondhand, or environmental, tobacco smoke on nicotine craving.”
The National Institute on Drug Abuse is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to ensure the rapid dissemination of research information and its implementation in policy and practice. Fact sheets on the health effects of drugs of abuse and information on NIDA research and other activities can be found on the NIDA home page at http://www.drugabuse.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®